The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 460-463

  Dawes, M ^a   Brett, S E ^a   Chowjenczyk, P J ^a   Mant, T G K ^b   Ritter, J M ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Essential hypertension; Forearm resistance vasculature; N(G) monomethyl L arginine; Nebivolol; Nitric oxide

Indexed keywords

CHOLESTEROL; N(G) METHYLARGININE; NEBIVOLOL;

ADULT; AGED; ARTERY CATHETERIZATION; ARTICLE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; FOREARM BLOOD FLOW; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SIDE EFFECT; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADOLESCENT; ADULT; AGED; BENZOPYRANS; DRUG INTERACTIONS; ENZYME INHIBITORS; ETHANOLAMINES; FEMALE; FOREARM; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OMEGA-N-METHYLARGININE; REGIONAL BLOOD FLOW; VASODILATION; VASODILATOR AGENTS;

EID: 0032841990     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00037.x     Document Type: Article

References (23)

1. Janssens WJ, van de Water A, Xhonnheux R, Reneman RS, van Neuten JM, Janssens PAJ. Nebivolol is devoid of intrinsic sympathomimetic activity. Eur J Pharmacol 1989; 159: 89-95.
2. Gao Y, Nagao T, Bond RA, Janssens WJ, Vanhoutte P. Nebivolol induces endothelium-dependent relaxation of canine coronary arteries. J Cardiovasc Pharmacol 1991; 7: 964-969.
3. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-1071.
4. Linder L, Kiowski W, Bühler FR, Lüscher TF, Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation 1990; 81: 1762-1767.
5. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
6. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
7. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994; 330: 1036-1040.
8. Taddei S, Virdis A, Mattei P, et al. Hypertension causes premature ageing of endothelial function in humans. Hypertension 1997; 29: 736-743.
9. Petrie J, O'Brien ET, Littler WA, de Swiet M. Recommendations on blood pressure measurement. Br Med J 1986; 293: 611-615.
10. White WB, Lund-Johanson P, MCCabe EJ, Omvic P. Clinical evaluation of the Accutracker II ambulatory blood pressure monitor: assessment of performance in two countries and comparison with sphygmomanometry and intra-arterial blood pressure at rest and during exercise. J Hypertens 1989; 7: 967-975.
11. Whitney RJ. The measurement of volume changes in human limbs. J Physiol 1953; 121: 1-27.
12. Hokanson DE, Sumner DS, Strandness DE Jr. An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEE Trans Biomed Eng 1975; 22: 25-29.
13. Dawes M, Chowienczyk PJ, Ritter JM. Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by β-adrenergic agonists in human forearm. Circulation 1997; 95: 2293-2297.
14. Lemho G, Iaccarino G, Vecchionc C, et al. Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm. J Clin Invest 1997; 100: 2007-2014.
15. Van Bortel LMAB, van Bark MA. Exercise tolerance with nebivolol and atenolol. Cardiovascular Drags Therapy 1992; 6: 239-247.
16. Van Bortel LMAB, Breed JGS, Jodsten J, Kragten A, Lustermans FATH, Mooij JMV. Nebivolol in hypertension: a double-blind placebo-controlled multicentre study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Phamacol 1993; 21: 856-862.
17. Stoleru L., Wijns W, van Eyll C, Bouvy T, Van Nueten I., Pouleur H. Effects of d-nebivolol and l-nebivolol on left ventricular systolic and diastolic function: comparison with d-l-nebivolol and atenolol. J Cardiovasc Pharmacol 1993; 22: 183-190.
18. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci (USA) 1990; 87: 5193-5197.
19. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits platelet adhesion to vascular endothclium. Lancet 1987; ii: 1057-1058.
20. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci (USA) 1991; 88: 4651-4655.
21. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777.
22. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14: 753-759.
23. Forte P, Copland M, Smith L, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis is reduced in essential hypertension, Lancet 1997; 349: 837-842.